CN113736768A - Pseudouridine synthetase mutant, mutant gene and application thereof in preparation of vitamin B2In (1) - Google Patents
Pseudouridine synthetase mutant, mutant gene and application thereof in preparation of vitamin B2In (1) Download PDFInfo
- Publication number
- CN113736768A CN113736768A CN202110950352.3A CN202110950352A CN113736768A CN 113736768 A CN113736768 A CN 113736768A CN 202110950352 A CN202110950352 A CN 202110950352A CN 113736768 A CN113736768 A CN 113736768A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- pseudouridine
- mutant
- bacillus subtilis
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P25/00—Preparation of compounds containing alloxazine or isoalloxazine nucleus, e.g. riboflavin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y504/00—Intramolecular transferases (5.4)
- C12Y504/99—Intramolecular transferases (5.4) transferring other groups (5.4.99)
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention discloses a pseudouridine synthetase mutant, a mutant gene and application thereof in preparing vitamin B2. Wherein the polypeptide amino acid sequence of the mutant only has the following mutations relative to the sequence shown in SEQ ID No. 3: histidine at 239 was mutated to leucine. The invention selects the 239 th amino acid to perform site-directed mutagenesis on the basis of pseudouridine synthetase yB, and carries out site-directed mutagenesis on the pseudouridine synthetase coding gene yly in bacillus subtilis BS-1B-to-Pseudouridine synthetase mutant (H239L) the strain containing Pseudouridine synthetase mutant (H239L) had increased vitamin B production compared to Bacillus subtilis BS-12The content of vitamin B in the product can reach 10.8%, and the vitamin B can be used for preparing vitamin B2Has great application value.
Description
Technical Field
The invention relates to pseudouridine synthetase mutant, mutant gene and application thereof in preparing vitamin B2Belonging to the field of biotechnology.
Background
Riboflavin (Riboflavin) also called vitamin B2Molecular formula is C17H20O6N4The vitamin B is a water-soluble vitamin in a vitamin B group, exists in two forms of Flavin Mononucleotide (FMN) and Flavin Adenine Dinucleotide (FAD) in organisms, participates in redox reaction as a coenzyme of some important oxidoreductases in organisms, and plays a role in delivering hydrogen. The lack of riboflavin causes the metabolic disorder of organisms, but neither humans nor animals can synthesize riboflavin by themselves and only ingest riboflavin from food, so that the production of riboflavin has a very wide market in the food, feed and pharmaceutical industries.
Currently, the industrial production methods of riboflavin include plant extraction methods, chemical synthesis methods, semi-synthesis methods, and microbial synthesis methods. Among them, the microbial synthesis method has advantages of low cost, environmental friendliness, renewable energy and the like, and gradually takes a leading position, and becomes a main method for most industrial production. Among a plurality of microorganisms capable of producing riboflavin, bacillus subtilis is taken as a non-pathogenic microorganism, has clear physiological metabolism and genetic background, is convenient to determine a metabolic target point and modify genetic engineering, has reliable safety, has long-term application of fermentation products in food and feed industries, and is very important for environmental, medical and industrial fermentation production. Secondly, the bacillus subtilis genetic engineering strain can excessively synthesize folic acid, inosine or guanosine and has the potential of providing enough precursors for excessive synthesis of riboflavin, so the bacillus subtilis genetic engineering strain gradually shows strong vitality in the microbial fermentation production of riboflavin and becomes a main production strain.
Riboflavin synthesis in bacillus subtilis (b.subtilis) requires two precursor substances, ribulose-5-phosphate (Ru5P) and guanine-5' -triphosphate (GTP), where Ru5P is derived from the pentose phosphate pathway and GTP is derived from the de novo purine synthesis pathway. Both of them finally synthesize riboflavin from the riboflavin synthesis pathway through 7-step reactions under the action of a number of riboflavin operons.
Pseudouridine synthase, encoded by the yB gene, catalyzes the production of pseudouridine from uracil. Among pyrimidine metabolic pathways, there are de novo and salvage synthetic pathways. Uracil reacts with phosphoribosylpyrophosphate (PRPP) in a salvage synthesis pathway to form uracil nucleotides. Thereby consuming free uracil and PRPP. While PRPP can be accumulated after uracil forms pseudouridine. PRPP, in turn, can be used as a precursor for de novo and salvage purine synthesis pathways to produce GTP, a precursor of riboflavin. Thus, it is thought that the pseudouridine synthase affects the production of riboflavin, i.e., the expression level of the pseudouridine synthase-encoding gene has a certain potential relationship with the production of riboflavin. At present, no pseudouridine synthase mutant gene has been used for vitamin B2And (5) reporting the synthesis.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a pseudouridine synthetase mutant, a mutant gene and application thereof in preparing vitamin B2The use of (1).
Firstly, the invention provides a pseudouridine synthetase mutant, which is characterized in that the polypeptide amino acid sequence only has the following mutations relative to the sequence shown in SEQ ID No. 3: histidine at 239 was mutated to leucine.
Preferably, according to the invention, the amino acid sequence is shown in SEQ ID No. 4.
Secondly, the present invention provides the coding gene of the pseudouridine synthetase mutant.
Preferably, according to the invention, the nucleotide sequence is shown as SEQ ID No. 2.
Accordingly, the third aspect of the present invention also provides an expression cassette, a recombinant vector containing a gene encoding the pseudouridine synthetase mutant. The recombinant vector is not particularly limited to the starting vector, and may be any vector known in the art as long as it can replicate in a host. For example, the vector includes, but is not limited to, a plasmid, a phage. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or in some cases, integrate into the genome itself.
More preferably a recombinant expression vector, more preferably a prokaryotic re-expression vector. Most preferred are expression vectors suitable for expression in Bacillus subtilis.
In a fourth aspect, the present invention provides a recombinant host cell containing a gene encoding said pseudouridine synthase mutant. Wherein said "host cell" is a cell having a meaning generally understood in the art, which is capable of introducing a gene encoding a mutant of the invention, the introduction being hereinafter referred to as recombinant host cell. The host cell of the invention may be a prokaryotic cell or a eukaryotic cell, preferably a prokaryotic cell, more preferably Bacillus subtilis.
In a fifth aspect, the present invention provides a pseudouridine synthetase mutant encoding gene in the production of vitamin B2The use of (1).
In a sixth aspect, the invention provides a method for enhancing the production of vitamin B by bacillus subtilis2The method of (1), wherein the pseudouridine synthetase encoding gene on the chromosome is subjected to site-directed mutagenesis to obtain vitamin B2Wherein the site-directed mutation is a substitution of the nucleotide encoding the 239 th histidine H of the coding gene with a nucleotide encoding leucine L, more particularly a mutation of the 716 th nucleotide a of the coding gene to T. The site-directed mutagenesis can be carried out by various methods known in the art.
Preferably, according to the invention, the original starting strain of Bacillus subtilis is Bacillus subtilis BS-1.
In a seventh aspect of the present invention, there is provided a method for preparing vitamin B using Bacillus subtilis obtained by the method of the above sixth aspect2The method of (1), which comprises culturing the Bacillus subtilis, and collecting vitamin B2More preferably further comprises purifying vitamin B2The step (2).
Wherein the Bacillus subtilis is culturedThe cultivation can be carried out according to the conventional methods in the art, such as shake flask cultivation, batch cultivation, continuous cultivation, fed-batch cultivation, etc., and suitable cultivation conditions such as temperature, time, pH of the medium, etc., can be selected as the case may be. In addition, vitamin B can be recovered or purified from the cells or the culture medium2The method of (a) can be carried out by a method conventional in the art, for example, filtration, anion exchange chromatography, crystallization, HPLC and the like.
The experimental procedures not described in detail in the present invention can be performed according to the routine experimental procedures in the technical field.
The invention has the technical characteristics that:
selecting pseudouridine synthetase gene yB in bacillus subtilis, and carrying out site-directed mutagenesis on the 239 th histidine of the pseudouridine synthetase gene yB to obtain a pseudouridine synthetase mutant (H239L). The activity of pseudouridine synthetase gene yB is obviously enhanced after mutation to drive uracil to generate pseudouridine, intracellular uracil is reduced after uracil generates pseudouridine, phosphoribosyl pyrophosphate (PRPP) can be accumulated, and PRPP can be used as a precursor of purine de novo synthesis pathway and salvage synthesis pathway, so that GTP synthesis can be enhanced, and vitamin B can be used as a precursor of purine de novo synthesis pathway and salvage synthesis pathway2Providing sufficient precursor, and increasing vitamin B2The yield of (2).
The invention has the beneficial effects that:
1. the invention takes pseudouridine synthetase yB as the basis, selects the 239 th amino acid to carry out site-directed mutagenesis, changes the pseudouridine synthetase encoding gene yB in bacillus subtilis BS-1 into a pseudouridine synthetase mutant (H239L), and compared with the bacillus subtilis BS-1, the strain containing the pseudouridine synthetase mutant (H239L) can improve the vitamin B production2The content of vitamin B in the product can reach 10.8%, and the vitamin B can be used for preparing vitamin B2Has great application value.
2. The research proves that the genetically engineered bacteria containing the mutant gene of the pseudouridine synthetase are biologically safe, and furthermore, the experiment shows that the gene mutation on the chromosome not only does not influence the growth of the bacteria, but also is beneficial to the growth of the bacteria, so that the content of the pseudouridine synthetase mutant gene can be further improvedStrain of pseudouridine synthetase mutant (H239L) produces vitamin B2The ability of the cell to perform.
Drawings
FIG. 1 shows VB of different Bacillus subtilis strains after fermentation for 41h2And (4) yield.
Detailed Description
The following examples and figures of the present invention are merely illustrative of specific embodiments for carrying out the invention and these should not be construed as limiting the invention and any changes which may be made without departing from the principles and spirit of the invention are within the scope of the invention.
The experimental techniques and experimental methods used in this example are conventional techniques unless otherwise specified. The materials, reagents and the like used in the present examples are all available from normal commercial sources unless otherwise specified.
High vitamin B production as described in this example2The preservation number of the bacillus subtilis is CGMCC NO. 4018. The Bacillus subtilis BS-1 has a preservation number of CGMCC NO. 4019. The Bacillus subtilis 168 is a Bacillus subtilis model strain.
The formula of the culture medium is as follows:
LB medium (g/L): 10 parts of sodium chloride, 10 parts of tryptone, 5 parts of yeast extract and 18 parts of agar powder added into a solid culture medium.
Fermentation medium (g/L): corn steep liquor dry powder 2, glucose 50, yeast extract 5, magnesium sulfate 0.05, ammonium sulfate 0.5 and the balance of distilled water.
Detection of OD 600:
and (3) measuring the turbidity of the fermentation liquor under 600nm by using a spectrophotometer, and quickly and accurately obtaining the biomass in the fermentation liquor. Accurately transferring a certain volume of fermentation liquor into a brown volumetric flask, fixing the volume with distilled water, uniformly mixing, placing into a cuvette, measuring the biomass at a wavelength of 600nm by taking the distilled water as a reference blank, and determining the OD600 as the reading multiplied by the dilution.
Vitamin B2The detection method comprises the following steps:
mixing the fermentation liquor uniformly, diluting the fermentation liquor to a proper multiple by using 0.01mol/L NaOH, mixing uniformly, carrying out light-shielding alkali dissolution for 20min, centrifuging at 12000rpm for 2min, taking supernate, taking 0.01mol/L NaOH as a blank, measuring absorbance (the display value is controlled between 0.2 and 0.8) at 444nm, and calculating the content of riboflavin according to the following formula: FB (mg/L) ═ (dilution times absorbance)/0.0321.
Example 1: confirmation and verification of yBgene mutation site
Since the yB gene is responsible for encoding pseudouridine synthase in Bacillus subtilis, driving uracil to produce pseudouridine, site-directed mutagenesis was chosen for the yB gene.
The inventors analyzed the highly conserved regions of the amino acid sequence of the pseudouridine synthetase encoded by the yyB gene using the Jalview software. Meanwhile, the protein simulation modeling of the pseudo uridine synthetase of the yyB gene is carried out by using a Swiss-Model tool, and the active center of the pseudo uridine synthetase is predicted by using a HotSpot Wizard 2.0. It was found that the 239 th position of the amino acid sequence of pseudouridine synthetase encoded by the yBgene is located near the active center and the highly conserved region, and it is highly probable that site-directed mutagenesis thereof results in an increase in the pseudouridine synthetase activity.
The inventor selects a high-yield vitamin B strain in the earlier stage2The bacillus subtilis (CGMCC NO.4018) can be fermented to produce vitamin B2. To further verify the role of the 239 th position of the pseudo uridine synthetase amino acid sequence encoded by the yyB gene, the genome of Bacillus subtilis 168 is taken as a reference genome, and vitamin B is highly produced2The Bacillus subtilis is sent to Jinzhi Biotechnology limited for sequencing to find vitamin B2Genes with an effect on competence. Through sequence comparison analysis, high-yield vitamin B is found2The bacillus subtilis has a large number of mutations, the total number of the mutations comprises 203 mutation sites, and through mutation statistics, the mutations relate to 50 genes, including the yyB gene.
Further, vitamin B is produced at a high yield2The genome of the bacillus subtilis is taken as a template, UPyB-F and DNyB-R are taken as primers, yB gene and upstream and downstream sequences are cloned to obtain a PCR product, and then the PCR product is sent to Jinzhi Biotech limited to carry out sequencing.Through sequence comparison analysis, high-yield vitamin B is found2Compared with Bacillus subtilis 168, the yBgene has mutation, and contains 4 mutation sites including 239 th site. Wherein, the nucleotide sequence of the yB gene of the Bacillus subtilis 168 is shown as SEQ ID No.1, and the amino acid sequence of the coded RNA helicase is shown as SEQ ID No. 3.
Except that the mutation at the 239 th site is non-synonymous mutation, the mutations at the other three sites are synonymous mutations, and the protein structure is not influenced. From the above results, it was found that the 239 th position in the amino acid sequence of pseudouridine synthase encoded by the yyB gene affects vitamin B2A key site of yield is designed according to the site, a pseudouridine synthetase mutant (H239L) is designed, the amino acid sequence of the pseudouridine synthetase mutant is shown as SEQ ID No.4, and the nucleotide sequence of the pseudouridine synthetase mutant is shown as SEQ ID No. 2.
Example 2: construction of engineering Strain 18-yB with yB Back-mutation
Amplifying a wild type UPylyB (containing DR) fragment with a joint by using a primer UPylyB-F, UPylyB-R (containing DR) and amplifying an araR (containing DR) fragment with a joint by using a primer araR-F, araR-R (containing DR) by using a Bacillus subtilis 168 chromosome as a template; using pC194 plasmid as a template, and amplifying a cat fragment with a joint by using a primer cat-F, cat-R; a chromosome of Bacillus subtilis 168 is taken as a template, and a downstream homology arm segment DNyB is amplified by using a primer DNyB-F, DNylyB-R, wherein the nucleotide sequence of the yB gene is shown as SEQ ID No.1, and the coded amino acid sequence is shown as SEQ ID No. 3.
And (3) performing fusion PCR by using a primer UPylyB-F, DNylyB-R by using the UPylyB fragment, the cat fragment, the araR fragment and the DNylyB fragment as templates to obtain an assembled fragment UCR-yB, detecting the assembled fragment UCR-yB correctly by nucleic acid electrophoresis, and recovering the gel to obtain a purified UCR-yB fragment.
Transformation of UCR-yB fragment Spizizen into high-yield vitamin B2The bacillus subtilis (CGMCC NO.4018) is coated on an LB solid plate containing 8mg/L chloramphenicol, colony PCR verification is carried out after 24h culture, intellectual sequencing is carried out when nucleic acid electrophoresis is correct, and the intermediate strain 4018-UCR-And (2) yB, wherein the nucleotide sequence of the yB gene is shown as SEQ ID No.1, and the coded amino acid sequence is shown as SEQ ID No. 3.
Selecting a single colony of an intermediate strain 4018-UCR-yB in a test tube containing 5mL LB, carrying out shake culture at 37 ℃ for 8h, then taking 200uL bacterial liquid to coat on an LB solid plate containing 40mg/L neomycin, carrying out colony PCR verification after culturing for 24h, carrying out accurate nucleic acid electrophoresis and carrying out intelligent sequencing, and obtaining an engineering strain 18-yB which removes a screening marker cat-araR through DR and contains the back mutation of the yB gene after the sequencing is accurate, wherein the nucleotide sequence of the yB gene is shown as SEQ ID No.1, and the coded amino acid sequence is shown as SEQ ID No. 3.
The primers used in this section were as follows:
the strains and plasmids used in this section were as follows:
example 3: construction of engineering Strain 19-yB containing yB mutant
Amplifying a UPylyB (containing DR) fragment with a joint and a point mutation by using a primer UPylyB-F, UPylyB-R (containing DR) by using a coding gene of an artificially synthesized pseudouridine synthetase mutant (H239L) as a template, and amplifying an araR (containing DR) fragment with a joint by using a primer araR-F, araR-R (containing DR); using pC194 plasmid as a template, and amplifying a cat fragment with a joint by using a primer cat-F, cat-R; a downstream homology arm fragment DNyB was amplified by using a primer DNyB-F, DNylyB-R, using the chromosome of B.subtilis 168 as a template. Wherein, the nucleotide sequence of the pseudouridine synthetase mutant (H239L) is shown as SEQ ID No.2, and the coded amino acid sequence is shown as SEQ ID No. 4.
And (3) performing fusion PCR by using a primer UPylyB-F, DNylyB-R by using the UPylyB fragment, the cat fragment, the araR fragment and the DNylyB fragment as templates to obtain an assembled fragment UCR-yB, detecting the assembled fragment UCR-yB correctly by nucleic acid electrophoresis, and recovering the gel to obtain a purified UCR-yB fragment.
Transforming the UCR-yB fragment Spizizen into Bacillus subtilis BS-1(CGMCC NO.4019), coating the Bacillus subtilis BS-1 on an LB solid plate containing 8mg/L chloramphenicol, culturing for 24H, then carrying out colony PCR verification, carrying out intelligent sequencing on nucleic acid electrophoresis correctly, and obtaining the intermediate strain 4019-UCR-yB containing the pseudouridine synthetase mutant (H239L) after the sequencing is correct. Wherein, the nucleotide sequence of the pseudouridine synthetase mutant (H239L) is shown as SEQ ID No.2, and the coded amino acid sequence is shown as SEQ ID No. 4.
Selecting a single colony of an intermediate strain 4019-UCR-yB, placing the single colony in a test tube containing 5mL LB, carrying out shake culture at 37 ℃ for 8H, then taking 200uL bacterial liquid, coating the bacterial liquid on an LB solid plate containing 40mg/L neomycin, carrying out colony PCR verification after culturing for 24H, carrying out intelligent sequencing on nucleic acid electrophoresis correctly, and obtaining an engineering strain 19-yB which has the internal chromosome removed the screening marker cat-araR through DR homologous recombination and contains the pseudouridine synthetase mutant (H239L). Wherein. The nucleotide sequence of the pseudouridine synthetase mutant (H239L) is shown as SEQ ID No.2, and the coded amino acid sequence is shown as SEQ ID No. 4.
The strains and plasmids used in this section were as follows:
example 4: evaluation of vitamin B in different strains2Capacity of production
Engineering strains 19-yB and Bacillus subtilis BS-1(CGMCC NO.4019) are respectively used as an experimental group and a control group for engineeringStrain 18-yB and high-yield vitamin B2Respectively taking Bacillus subtilis (CGMCC NO.4018) as experimental group and control group, and performing strain vitamin B2And (5) evaluating the production capacity.
1. Conditions for culturing the strains
LB solid plates containing 20mg/L neomycin were streaked with an inoculating needle under aseptic conditions, and inverted in an incubator at 37 ℃ for 24-48 hours to obtain freshly activated single colonies. A single colony was picked with an inoculating needle, streaked on an LB solid slant containing 20mg/L neomycin, and cultured in an incubator at 37 ℃ for 48 hours. Scraping 1/3 thallus Porphyrae on the inclined plane, inoculating into 500mL baffle triangular flask containing 70mL fermentation medium (3 parallel strains), culturing at 37 deg.C under shaking at 200rpm for 41 hr, and measuring OD600 and vitamin B in the fermentation broth2And (4) yield.
2. Different strains OD600 and vitamin B2Comparison of yields
Engineered Strain 19-yB and Bacillus subtilis BS-1, Strain 19-yB vitamin B containing Pseudouridine synthetase mutant (H239L)2The yield is improved by 10.8 percent, the engineering strain is 18-yB and the high-yield vitamin B2Return mutant Strain 18-yB vitamin B compared to Bacillus subtilis2The yield decreased by 9.8% (see table 4 below and figure 1).
The experimental result shows that the invention takes pseudouridine synthetase yB as the basis, selects the 239 th amino acid for site-directed mutagenesis to change the pseudouridine synthetase yB in bacillus subtilis BS-1 into a pseudouridine synthetase mutant (H239L), and compared with the original strain, the strain containing the pseudouridine synthetase mutant (H239L) can improve the vitamin B production2The content of vitamin B in the product can reach 10.8%, and the vitamin B can be used for preparing vitamin B2Has great application value.
In addition, the genetically engineered bacteria containing the mutant gene of the pseudouridine synthase are biologically safe, and furthermore, the biological quantity of the engineered strain 19-yB containing the mutant gene of the pseudouridine synthase is higher than that of the original strain of the bacillus subtilisBacillus BS-1, which shows that point mutation of yyB gene is beneficial to growth of thallus, can further improve the production of vitamin B by the strain containing pseudouridine synthetase mutant (H239L)2The ability of the cell to perform.
SEQUENCE LISTING
<110> New drug industry Co., Ltd
<120> pseudouridine synthetase mutant, mutant gene and application thereof in preparation of vitamin B2
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 912
<212> DNA
<213> Bacillus subtilis
<400> 1
atgaatcaaa ttgatataac cgcttcagaa gaacaaaaaa gtgagcggat tgataaattt 60
ttggcatcga ctgagaatga ttggtcaaga acccaggttc agcaatgggt aaaagacgga 120
caggttgtcg tgaacggaag cgcggtgaaa gcgaattata aaattcagcc gggtgatcag 180
gtgaccgtca ctgtacctga accggaagcg ctcgacgtcc tggcagagcc tatggatctg 240
gatatttatt atgaggacca ggatgtgctg gtcgtcaaca aacctcgcgg aatggttgtt 300
cacccagcac ccgggcatct tacgggcaca cttgtaaacg gtcttatggc tcattgcaca 360
gacctttccg gaataaatgg tgtgatgcgc ccgggtattg ttcacagaat cgataaggac 420
acgtccggtt tattaatggt ggcgaaaaat gatatggcgc acgagtcact cgtaaaccaa 480
ttggtcaaca aaacggtcac gcggaaatat acggcggttg tccacgggct tatttctcat 540
gatgacggca caattgacgc gccgatcgga cgggataaaa aagaccgtca aagcatgact 600
gtgacacgtg atggcaaaaa cgctgtcact cattttcatg tgcttgagcg ttttcaggat 660
tttacgttag tggagtgcca gcttgaaaca gggagaaccc atcaaattcg tgttcatatg 720
aaatatatcg gattcccatt agcaggcgat ccgaaatacg gcccaagaaa aacaatcgac 780
tttaatggcc aagcgcttca cgcgggagtt ttaggttttg accatccacg aacaggagaa 840
tatgtcgaat ttgaagcgcc gcttcccgag gatatggcag aattaatcga aaacctcaga 900
aaaaacggtt ga 912
<210> 2
<211> 912
<212> DNA
<213> Bacillus subtilis
<400> 2
atgaatcaaa ttgatataac cgcttcagaa gaacaaaaaa gtgagcggat tgataaattt 60
ttggcatcga ctgagaatga ttggtcaaga acccaggttc agcaatgggt aaaagacgga 120
caggttgtcg tgaacggaag cgcggtgaaa gcgaattata aaattcagcc gggtgatcag 180
gtgaccgtca ctgtacctga accggaagcg ctcgacgtcc tggcagagcc tatggatctg 240
gatatttatt atgaggacca ggatgtgctg gtcgtcaaca aacctcgcgg aatggttgtt 300
cacccagcac ccgggcatct tacgggcaca cttgtaaacg gtcttatggc tcattgcaca 360
gacctttccg gaataaatgg tgtgatgcgc ccgggtattg ttcacagaat cgataaggac 420
acgtccggtt tattaatggt ggcgaaaaat gatatggcgc acgagtcact cgtaaaccaa 480
ttggtcaaca aaacggtcac gcggaaatat acggcggttg tccacgggct tatttctcat 540
gatgacggca caattgacgc gccgatcgga cgggataaaa aagaccgtca aagcatgact 600
gtgacacgtg atggcaaaaa cgctgtcact cattttcatg tgcttgagcg ttttcaggat 660
tttacgttag tggagtgcca gcttgaaaca gggagaaccc atcaaattcg tgttcttatg 720
aaatatatcg gattcccatt agcaggcgat ccgaaatacg gcccaagaaa aacaatcgac 780
tttaatggcc aagcgcttca cgcgggagtt ttaggttttg accatccacg aacaggagaa 840
tatgtcgaat ttgaagcgcc gcttcccgag gatatggcag aattaatcga aaacctcaga 900
aaaaacggtt ga 912
<210> 3
<211> 303
<212> PRT
<213> Bacillus subtilis
<400> 3
Met Asn Gln Ile Asp Ile Thr Ala Ser Glu Glu Gln Lys Ser Glu Arg
1 5 10 15
Ile Asp Lys Phe Leu Ala Ser Thr Glu Asn Asp Trp Ser Arg Thr Gln
20 25 30
Val Gln Gln Trp Val Lys Asp Gly Gln Val Val Val Asn Gly Ser Ala
35 40 45
Val Lys Ala Asn Tyr Lys Ile Gln Pro Gly Asp Gln Val Thr Val Thr
50 55 60
Val Pro Glu Pro Glu Ala Leu Asp Val Leu Ala Glu Pro Met Asp Leu
65 70 75 80
Asp Ile Tyr Tyr Glu Asp Gln Asp Val Leu Val Val Asn Lys Pro Arg
85 90 95
Gly Met Val Val His Pro Ala Pro Gly His Leu Thr Gly Thr Leu Val
100 105 110
Asn Gly Leu Met Ala His Cys Thr Asp Leu Ser Gly Ile Asn Gly Val
115 120 125
Met Arg Pro Gly Ile Val His Arg Ile Asp Lys Asp Thr Ser Gly Leu
130 135 140
Leu Met Val Ala Lys Asn Asp Met Ala His Glu Ser Leu Val Asn Gln
145 150 155 160
Leu Val Asn Lys Thr Val Thr Arg Lys Tyr Thr Ala Val Val His Gly
165 170 175
Leu Ile Ser His Asp Asp Gly Thr Ile Asp Ala Pro Ile Gly Arg Asp
180 185 190
Lys Lys Asp Arg Gln Ser Met Thr Val Thr Arg Asp Gly Lys Asn Ala
195 200 205
Val Thr His Phe His Val Leu Glu Arg Phe Gln Asp Phe Thr Leu Val
210 215 220
Glu Cys Gln Leu Glu Thr Gly Arg Thr His Gln Ile Arg Val His Met
225 230 235 240
Lys Tyr Ile Gly Phe Pro Leu Ala Gly Asp Pro Lys Tyr Gly Pro Arg
245 250 255
Lys Thr Ile Asp Phe Asn Gly Gln Ala Leu His Ala Gly Val Leu Gly
260 265 270
Phe Asp His Pro Arg Thr Gly Glu Tyr Val Glu Phe Glu Ala Pro Leu
275 280 285
Pro Glu Asp Met Ala Glu Leu Ile Glu Asn Leu Arg Lys Asn Gly
290 295 300
<210> 4
<211> 303
<212> PRT
<213> Bacillus subtilis
<400> 4
Met Asn Gln Ile Asp Ile Thr Ala Ser Glu Glu Gln Lys Ser Glu Arg
1 5 10 15
Ile Asp Lys Phe Leu Ala Ser Thr Glu Asn Asp Trp Ser Arg Thr Gln
20 25 30
Val Gln Gln Trp Val Lys Asp Gly Gln Val Val Val Asn Gly Ser Ala
35 40 45
Val Lys Ala Asn Tyr Lys Ile Gln Pro Gly Asp Gln Val Thr Val Thr
50 55 60
Val Pro Glu Pro Glu Ala Leu Asp Val Leu Ala Glu Pro Met Asp Leu
65 70 75 80
Asp Ile Tyr Tyr Glu Asp Gln Asp Val Leu Val Val Asn Lys Pro Arg
85 90 95
Gly Met Val Val His Pro Ala Pro Gly His Leu Thr Gly Thr Leu Val
100 105 110
Asn Gly Leu Met Ala His Cys Thr Asp Leu Ser Gly Ile Asn Gly Val
115 120 125
Met Arg Pro Gly Ile Val His Arg Ile Asp Lys Asp Thr Ser Gly Leu
130 135 140
Leu Met Val Ala Lys Asn Asp Met Ala His Glu Ser Leu Val Asn Gln
145 150 155 160
Leu Val Asn Lys Thr Val Thr Arg Lys Tyr Thr Ala Val Val His Gly
165 170 175
Leu Ile Ser His Asp Asp Gly Thr Ile Asp Ala Pro Ile Gly Arg Asp
180 185 190
Lys Lys Asp Arg Gln Ser Met Thr Val Thr Arg Asp Gly Lys Asn Ala
195 200 205
Val Thr His Phe His Val Leu Glu Arg Phe Gln Asp Phe Thr Leu Val
210 215 220
Glu Cys Gln Leu Glu Thr Gly Arg Thr His Gln Ile Arg Val Leu Met
225 230 235 240
Lys Tyr Ile Gly Phe Pro Leu Ala Gly Asp Pro Lys Tyr Gly Pro Arg
245 250 255
Lys Thr Ile Asp Phe Asn Gly Gln Ala Leu His Ala Gly Val Leu Gly
260 265 270
Phe Asp His Pro Arg Thr Gly Glu Tyr Val Glu Phe Glu Ala Pro Leu
275 280 285
Pro Glu Asp Met Ala Glu Leu Ile Glu Asn Leu Arg Lys Asn Gly
290 295 300
Claims (10)
1. A pseudouridine synthase mutant, characterized in that the polypeptide amino acid sequence thereof has only the following mutations relative to the sequence shown in SEQ ID No. 3: histidine at 239 was mutated to leucine.
2. The mutant pseudouridine synthase according to claim 1, wherein the amino acid sequence is represented by SEQ ID No. 4.
3. The gene encoding a pseudouridine synthase mutant according to claim 1.
4. The coding gene of claim 3, wherein the nucleotide sequence is as shown in SEQ ID No. 2.
5. A recombinant vector comprising a gene encoding the pseudouridine synthase mutant according to claim 3.
6. A recombinant host cell comprising a gene encoding the pseudouridine synthase mutant according to claim 3.
7. Use of the pseudouridine synthase mutant according to claim 1 or the pseudouridine synthase mutant according to claim 3 in production of vitamin B2The use of (1).
8. Enhancing vitamin B production of bacillus subtilis2The method is characterized in that the RNA helicase coding gene of the amino acid sequence shown as SEQ ID No.3 on the chromosome is subjected to site-directed mutagenesis to obtain the vitamin B2Wherein the site-directed mutation is site-directed mutation of a nucleotide encoding histidine at 239 th position of the encoded gene to encode leucine.
9. The method of claim 8, wherein the bacillus subtilis is bacillus subtilis BS-1 as the starting strain.
10. A method for preparing vitamin B by using Bacillus subtilis obtained by the method of claim 8 or 92The method of (1), comprising culturing said Bacillus subtilis, and collecting vitamin B2The step (2).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110950352.3A CN113736768B (en) | 2021-08-18 | 2021-08-18 | Pseudo uridine synthetase mutant, mutant gene and application thereof in preparation of vitamin B2 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110950352.3A CN113736768B (en) | 2021-08-18 | 2021-08-18 | Pseudo uridine synthetase mutant, mutant gene and application thereof in preparation of vitamin B2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113736768A true CN113736768A (en) | 2021-12-03 |
| CN113736768B CN113736768B (en) | 2023-06-23 |
Family
ID=78731671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110950352.3A Active CN113736768B (en) | 2021-08-18 | 2021-08-18 | Pseudo uridine synthetase mutant, mutant gene and application thereof in preparation of vitamin B2 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113736768B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000029547A1 (en) * | 1998-11-12 | 2000-05-25 | Smithkline Beecham Corporation | YfiI PSEUDOURIDINE SYNTHASE |
| US20080050774A1 (en) * | 2004-01-09 | 2008-02-28 | Novozymes A/S | Bacillus licheniformis chromosome |
| CA3162352A1 (en) * | 2010-10-01 | 2012-04-05 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| WO2019191232A2 (en) * | 2018-03-27 | 2019-10-03 | University Of Rochester | Nucleic acid molecules for pseudouridylation |
| CN110964769A (en) * | 2019-11-29 | 2020-04-07 | 河南巨龙生物工程股份有限公司 | Method for improving yield of riboflavin produced by fermenting bacillus subtilis |
| CN111393515A (en) * | 2020-06-03 | 2020-07-10 | 中国科学院天津工业生物技术研究所 | Ribonucleotide reductase transcription inhibitor mutant, mutant gene and application of mutant gene in preparation of vitamin B2 |
-
2021
- 2021-08-18 CN CN202110950352.3A patent/CN113736768B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000029547A1 (en) * | 1998-11-12 | 2000-05-25 | Smithkline Beecham Corporation | YfiI PSEUDOURIDINE SYNTHASE |
| US6110723A (en) * | 1998-11-12 | 2000-08-29 | Smithkline Beecham Corporation | Yfii pseudouridine synthase |
| US20080050774A1 (en) * | 2004-01-09 | 2008-02-28 | Novozymes A/S | Bacillus licheniformis chromosome |
| CA3162352A1 (en) * | 2010-10-01 | 2012-04-05 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| WO2019191232A2 (en) * | 2018-03-27 | 2019-10-03 | University Of Rochester | Nucleic acid molecules for pseudouridylation |
| CN112020557A (en) * | 2018-03-27 | 2020-12-01 | 罗切斯特大学 | Nucleic acid molecules for pseudoglycosidation |
| CN110964769A (en) * | 2019-11-29 | 2020-04-07 | 河南巨龙生物工程股份有限公司 | Method for improving yield of riboflavin produced by fermenting bacillus subtilis |
| CN111393515A (en) * | 2020-06-03 | 2020-07-10 | 中国科学院天津工业生物技术研究所 | Ribonucleotide reductase transcription inhibitor mutant, mutant gene and application of mutant gene in preparation of vitamin B2 |
Non-Patent Citations (2)
| Title |
|---|
| 王德宝 等: "《转移核糖核酸 结构、功能与合成》", 31 December 1995, 浙江科学技术出版社 * |
| 王敏 等: "核黄素合成途径关键酶:新型生防制剂筛选靶标", 《农药》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113736768B (en) | 2023-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111393515B (en) | Ribonucleotide reductase transcription inhibitor mutant, mutant gene and application of mutant gene in preparation of vitamin B2 | |
| US10876099B2 (en) | Preparation and application of cyclodextrin glucosyltransferase mutant | |
| CN112359006B (en) | Recombinant microorganism producing cytosine and method for producing cytosine | |
| CN112143751B (en) | Bacillus subtilis engineering bacterium for high nucleoside yield, and construction method and application thereof | |
| CN106497895B (en) | Leucine dehydrogenase mutant, encoding gene, carrier, engineering bacteria and its application | |
| CN114480240A (en) | Genetic engineering bacterium for producing fucosyllactose and production method thereof | |
| CN112538453A (en) | Bacillus subtilis for producing riboflavin and construction method and application thereof | |
| CN112225785B (en) | GntR family transcription inhibitor mutant, mutant gene and application thereof in preparation of vitamin B2In (1) | |
| JP7489134B2 (en) | D-psicose 3-epimerase producing strain and use thereof | |
| JP5813512B2 (en) | Riboflavin production method | |
| CN111996155B (en) | Method for improving production capacity of L-histidine producing strain | |
| CN113736768B (en) | Pseudo uridine synthetase mutant, mutant gene and application thereof in preparation of vitamin B2 | |
| CN111393514B (en) | Peroxide transcription inhibitor mutant, mutant gene and application thereof in preparation of vitamin B2 | |
| CN113025550B (en) | High yield of vitamin B2Bacillus subtilis engineering strain, construction and application thereof | |
| CN113736761B (en) | RNA helicase mutant, mutant gene and application thereof in preparation of vitamin B 2 Application in (a) | |
| CN112458073B (en) | H-protein mutant and application thereof | |
| CN114806995A (en) | Construction and application of genetically engineered bacterium for efficiently synthesizing tetrahydropyrimidine based on acetyl coenzyme A metabolic modification | |
| CN115806926A (en) | Genetically engineered strain for producing pseudouridine and construction method and application thereof | |
| CN114480461A (en) | Recombinant microorganism for producing beta-nicotinamide mononucleotide and construction method and application thereof | |
| Taran et al. | Synthesis of 2-chloro-2′-deoxyadenosine by microbiological transglycosylation using a recombinant Escherichia coli strain | |
| JP2022535651A (en) | Systems, methods and compositions for recombinant in vitro transcription and translation using thermophilic proteins | |
| CN110819605A (en) | Methionine synthetase mutant, mutant gene and application thereof in preparation of vitamin B12In (1) | |
| KR101694461B1 (en) | GRAS strain-derived enzyme obtained by molecular evlution and GRAS Corynebaterium glutamicum having the same | |
| CN117660577B (en) | Application of LtaSA protein or coding gene thereof in riboflavin production | |
| CN115058402B (en) | Nicotinamide ribokinase mutant and coding gene and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |